CPRX Share Price

Open 2.44 Change Price %
High 2.46 1 Day 0.00 0.00
Low 2.39 1 Week 0.03 1.24
Close 2.44 1 Month -0.31 -11.27
Volume 221186 1 Year 1.19 95.20
52 Week High 3.20
52 Week Low 0.94
CPRX Important Levels
Resistance 2 2.50
Resistance 1 2.48
Pivot 2.43
Support 1 2.40
Support 2 2.38
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
ASTI 0.00 0.00%
More..
NASDAQ USA Top Gainers Stocks
RITT 0.02 100.00%
LOCM 0.09 50.00%
NETE 0.72 44.00%
SCHS 0.04 33.33%
MRGE 0.55 30.95%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PGRX 0.05 25.00%
ESMC 0.12 20.00%
More..
NASDAQ USA Top Losers Stocks
DEER 0.00 -100.00%
CAFI 0.00 -100.00%
ORIG 24.00 -96.52%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CPWR 1.00 -60.00%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX)

CPRX Technical Analysis 2
As on 22nd Sep 2017 CPRX Share Price closed @ 2.44 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.83 & Strong Sell for SHORT-TERM with Stoploss of 2.77 we also expect STOCK to react on Following IMPORTANT LEVELS.
CPRX Target for September
1st Target up-side 3
2nd Target up-side 3.18
3rd Target up-side 3.35
1st Target down-side 2.5
2nd Target down-side 2.32
3rd Target down-side 2.15
CPRX Other Details
Segment EQ
Market Capital 44575204.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.catalystpharma.com
CPRX Address
CPRX
355 Alhambra Circle
Suite 1500
Coral Gables, FL 33134
United States
Phone: 305-529-2522
CPRX Latest News
Interactive Technical Analysis Chart Catalyst Pharmaceutical Partners, Inc. ( CPRX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Catalyst Pharmaceutical Partners, Inc.
CPRX Business Profile
Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company. The Company is focused on the development and commercialization of prescription drugs targeting addiction diseases and disorders of the central nervous system with a focus on the treatment of addiction and epilepsy. As of December 31, 2011, the Company had two drugs in development: CPP-109 and CPP-115. of December 31, 2011, it was evaluating its drug candidate, CPP-109 for the treatment of cocaine addiction. As of December 31, 2011, the Company was in the early stages of developing CPP-115, another GABA aminotransferase inhibitor. It has identified two market opportunities that can be exploited by pharmacotherapies that inhibit GABA-aminotransferase (GABA-AT): drug addiction and epilepsy.